- cafead Dec 22, 2022 at 11:22: AM
via RNA expert ProQR Therapeutics is ending a tough year on a high note thanks to a $75 million expansion of a genetic medicines partnership with Eli Lilly.
This expansion should be good news for the Dutch biotech, which cut 30% of its staff in the spring after a phase 2/3 med called sepofarsen failed. In August, ProQR said it would seek partnerships for its ophthalmology programs. The company refocused on its RNA-editing technology and wound down clinical trials for other candidates to preserve cash in the meantime.
article source
This expansion should be good news for the Dutch biotech, which cut 30% of its staff in the spring after a phase 2/3 med called sepofarsen failed. In August, ProQR said it would seek partnerships for its ophthalmology programs. The company refocused on its RNA-editing technology and wound down clinical trials for other candidates to preserve cash in the meantime.
article source